
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Seth Wander, MD, PhD, a medical oncologist at the Massachusetts General Hospital and instructor in medicine at Harvard Medical School, discusses the efficacy of elacestrant (Orserdu) in real-world data for patients with ESR1-mutated breast cancer. At the …